Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

@article{Anglesio2008MutationOE,
  title={Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.},
  author={Michael S Anglesio and J. Markowitz Arnold and Joshy George and Anna V. Tinker and Richard W. Tothill and Nicola Waddell and Lisa A. Simms and Bianca Locandro and Sian Fereday and Nadia Traficante and Peter H. Russell and Raghwa Sharma and Michael J. Birrer and Anna deFazio and Georgia Chenevix-Trench and David D. L. Bowtell},
  journal={Molecular cancer research : MCR},
  year={2008},
  volume={6 11},
  pages={1678-90}
}
Approximately, 10% to 15% of serous ovarian tumors fall into the category designated as tumors of low malignant potential (LMP). Like their invasive counterparts, LMP tumors may be associated with extraovarian disease, for example, in the peritoneal cavity and regional lymph nodes. However, unlike typical invasive carcinomas, patients generally have a favorable prognosis. The mutational profile also differs markedly from that seen in most serous carcinomas. Typically, LMP tumors are associated… CONTINUE READING
53 Citations
96 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 96 references

Sequence mutations and Activation of RAS-MAPK Pathway in Serous LMP Tumors

  • K Nakayama, N Nakayama, RJ Kurman
  • Mol Cancer Res
  • 2008
2 Excerpts

Similar Papers

Loading similar papers…